





RESPONSE TO COMMENT ON PATHAK ET AL.

Severe Hypoglycemia Requiring Medical Intervention in a Large Cohort of Adults With Diabetes Receiving Care in U.S. Integrated Health Care Delivery Systems: 2005–2011. Diabetes Care 2016;39:363–370

Diabetes Care 2017;40:e26 | DOI: 10.2337/dci16-0037

In a comment (1) on our article in Diabetes Care (2), Dr. Philip Home posits that the association of severe hypoglycemic events with other medical conditions and the use of diagnoses from hospitalized patients could explain the high event rate noted in our study compared with other reports based in the ambulatory care setting. Home correctly notes that use of secondary hypoglycemia diagnoses and diagnoses from inpatient hospital admissions may overestimate the rate of severe hypoglycemia as the primary cause of visits in emergency departments or that result in hospital admission. To clarify, our analyses relied on only primary or principal diagnosis codes. In addition, only 20% of our events included only inpatient diagnosis codes. Although our event rate is higher than those reported in clinical trials (1.4–1.6 events per 100 person-years (2) vs. 0.3–1.0 events per 100 person-years [3–5]), there are several potential explanations for higher hypoglycemia rates in community settings. We hope further work will develop additional methods for minimizing misclassification in hypoglycemia definitions and will clarify factors that increase hypoglycemia risk in community settings.

Duality of Interest. E.B.S. was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant K23DK099237. E.R.S. served as a consultant for Sanofi. No other potential conflicts of interest relevant to this article were reported.

References

1. Home PD. Comment on Pathak et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving

Ram D. Pathak, ¹ Emily B. Schroeder, ² Elizabeth R. Seaquist, ³ Chan Zeng, ² Jennifer Elston Lafata, ^{4,5} Abraham Thomas, ⁵ Jean M. Lawrence, ⁶ Andrew J. Karter, ⁷ John F. Steiner, ² Jodi Segal, ⁸ and Patrick J. O'Connor, ⁹ for the SUPREME-DM Study Group

care in U.S. integrated health care delivery systems: 2005–2011. Diabetes Care 2016;39:363–370 (Letter). Diabetes Care 2017;40:e25. DOI: 10.2337/dc16-0527.

- 2. Pathak RD, Schroeder EB, Seaquist ER, et al.; SUPREME-DM Study Group. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005–2011. Diabetes Care 2016;39: 363–370
- 3. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:129–139
- 4. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559
- 5. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucoselowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care 2015;38: 22–28

¹Marshfield Clinic, Marshfield, WI

²Kaiser Permanente Colorado, Institute for Health Research, Denver, CO

³Department of Medicine, University of Minnesota, Minneapolis, MN

⁴Virginia Commonwealth University, Richmond, VA

⁵Henry Ford Health System, Detroit, MI

⁶Kaiser Permanente Southern California, Pasadena, CA

⁷Kaiser Permanente Northern California, Oakland, CA

⁸Johns Hopkins University, Baltimore, MD

⁹HealthPartners Institute for Education and Research, Minneapolis, MN